Scarica l'app Stockscreener
7.71
3.49%
0.26
Dopo l'orario di chiusura:
7.89
0.18
+2.33%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Verastem Inc Borsa (VSTM) Ultime notizie
Does Verastem (VSTM) Have the Potential to Rally 79% as Wall Street Analysts Expect? - Zacks Investment Research
BTIG reiterates Buy rating on Verastem, $18 price target - TradingView
BTIG keeps its Buy rating for Verastem stock - AD HOC NEWS
This Insider Has Just Sold Shares In Verastem - Simply Wall Street
This Insider Has Just Sold Shares In Verastem - Simply Wall Street
Verastem's cancer drug sales hit $25.1M in Q2 '26; key trial data expected in October - Pluang
Verastem: A Two-For-One Clinical Readout In October And A Commercial Launch (NASDAQ:VSTM) - Seeking Alpha
Strength Seen in Genmab (GMAB): Can Its 10.7% Jump Turn into More Strength? - Zacks Investment Research
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
VSTM Reiterates by HC Wainwright & Co. -- Price Target Maintained at $18 - GuruFocus
VSTM Reiterated by BTIG -- Price Target Maintained at $18 - GuruFocus
Verastem Oncology Announces New RAMP 201 Molecular Profiling and External Control Arm Analyses Describing Outcomes for Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at IGCS 2026 - BioSpace
To cover tax withholding, Verastem (VSTM) CEO sells 44,121 shares at $8 each. - Stock Titan
A 2,566-share sale at $8 covers vesting taxes for Verastem (VSTM) CFO Daniel Calkins. - Stock Titan
To cover vesting taxes, Dan Paterson plans to sell 44,121 shares of Verastem (VSTM). - Stock Titan
Preferred dividends of Verastem, Inc. – HAN:2VSA - TradingView
Discontinued operations of Verastem, Inc. – HAN:2VSA - TradingView
Verastem, Inc. Actuals & Estimates (HAN:2VSA) - TradingView
Verastem (NasdaqCM:VSTM) Stock Forecast & Analyst Predictions - Simply Wall Street
Verastem (VSTM) Shares React to Positive Two-Year Phase 2 RAMP 201 Study Results in Ovarian Cancer - GuruFocus
Half of patients with a specific ovarian cancer mutation stayed on treatment for over a year. - Stock Titan
Cantor Fitzgerald reiterates Overweight on Verastem stock ahead of data By Investing.com - Investing.com Nigeria
Cantor Fitzgerald reiterates Overweight on Verastem stock ahead of data - Investing.com
Understanding the Setup: (VSTM) and Scalable Risk - Stock Traders Daily
Verastem to present cancer treatment study data at IGCS meeting - Investing.com
Two ovarian cancer studies are selected for Montreal talks. One studied Japanese patients. - Stock Titan
Verastem Oncology Announces Late-Breaking Oral Presentation of RAMP 201 Low-Grade Serous Ovarian Cancer Molecular Profiling and Tumor Biomarker Analysis at IGCS 2026 Annual Global Meeting - Business Wire
Verastem CFO Daniel Calkins sells $423 in company stock - Investing.com
Form 4 Verastem Inc For: 23 September - Investing.com India
Verastem CFO Daniel Calkins sells $423 in company stock By Investing.com - Investing.com Canada
Verastem (VSTM) CFO Daniel Calkins Sells 55 Shares, Insider Owne - GuruFocus
After selling 55 shares, Verastem (VSTM) CFO Daniel Calkins directly owned 118,014 shares. - Stock Titan
Verastem Highlights Ovarian Cancer Launch, KRAS G12D Program at H.C. Wainwright - Yahoo Finance
Verastem Highlights Ovarian Cancer Launch, KRAS G12D Program at H.C. Wainwright - TradingView
H.C. Wainwright Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $18 - Moomoo
Verastem Inc. Share PriceVSTM, RNS News, Articles, Quotes, & Charts (NASDAQ:VSTM) - Proactive financial news
Verastem's Shares Not Fully Valuing its Growth Potential, RBC Says - marketscreener.com
Verastem's Shares Not Fully Valuing its Growth Potential, RBC Says - Yahoo Finance
Verastem, Inc. (VSTM) Stock Analysis: Unveiling a 94% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
Verastem Repeat Insider Selling Not A Positive Indicator - Moomoo
Wolfe Research Initiates Verastem at Outperform - Yahoo Finance
H.C. Wainwright Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $18 - Moomoo
VSTM Reiterated by HC Wainwright & Co. -- Price Target Maintained at $18 - GuruFocus
Verastem CSO Pachter: The First RAS Drug Is a Floor, Not a Ceiling - finance.biggo.com
VSTM Reiterated by BTIG -- Price Target Maintained at $18 - GuruFocus
Verastem at Cantor conference: dual-track growth, big bets By Investing.com - Investing.com India
Verastem at Cantor conference: dual-track growth, big bets By Investing.com - Investing.com Canada
VSTM: Verastem Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
3.32%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):